Pharmabiz12d
SEC recommends approval for update of Biological E's Covid-19 vaccine for Omicron XBB 1.5 variant
Gireesh Babu, New Delhi Tuesday, September 10, 2024, 08:00 Hrs [IST] ...
The Hindu25d
Indian Immunologicals Ltd develops needle-free COVID-19 intranasal booster vaccine in collaboration with Australian university
1 and KP.2, were responsible for the recent surge in COVID-19 cases in India. He said these strains evolved from the JN1 Omicron variant and were highly transmissible, and while there has been no ...
Hybrid COVID variant XEC is more contagious: What to know about the new strain
The side effects of newly discovered COVID strain XEC might not be more severe, but appears to be more contagious, ...
New COVID vaccines may be coming to Australia. Here’s what to know about the JN.1 shots
In Australia, our process differs slightly and tends to take a little longer. The TGA’s website indicates applications for ...
New Scientist1d
What to know about the new covid-19 XEC variant
A new covid-19 variant called XEC may spread more easily than past variants, but current vaccines are still effective against ...
New COVID-19 variant making its way through US: What to know about XEC variant, symptoms
The CDC has not confirmed whether there are any unique symptoms from the XEC variant. USA TODAY has reached out to CDC ...
COVID variant XEC seeing rapid growth across globe and the U.S. Here's what to know
A new COVID variant XEC is spreading rapidly worldwide and making its way through the U.S. Here's what you need to know.
New XEC COVID variant is on the rise. What are its symptoms, and will it cause a surge?
The new and contagious XEC COVID-19 variant is spreading rapidly in several countries. Will it cause a surge in the U.S.?
Healthline2d
COVID-19 Symptoms May Show Up in This Order
By mid-September, the Centers for Disease Control and Prevention reported the Omicron subvariant KP.3.1.1 accounted for most COVID-19 cases. KP.3.1.1 is a member of a group of variants nicknamed ...
Australian Broadcasting Corporation18d
New COVID-19 vaccines targeting JN.1 variant under review by Therapeutic Goods Administration
Last month, pharmaceutical companies Pfizer and Moderna both submitted applications to the Therapeutic Goods Administration (TGA) for COVID-19 jabs that target the Omicron sub-variant JN.